Mechanisms
Lifestyle and hormones can modestly influence Lp(a) levels, a review of non-pharmacological Lp(a) management (Curr Med Chem 2017)
Original title: Lipoprotein (a) Management: Lifestyle and Hormones
This review by Garcia-Rios, Leon-Acuna, Lopez-Miranda and Perez-Martinez, part of a review series on Lp(a) biology, examines how lifestyle factors, hormones and other physiological or pathological conditions influence plasma Lp(a) concentrations, given renewed interest in Lp(a) as a cardiovascular risk factor amid rising cardiovascular disease rates despite current preventive and therapeutic efforts. The authors review the current understanding of these non-pharmacological influences on Lp(a), aiming to identify factors that might mitigate Lp(a) harmful cardiovascular effects.
Original abstract
Cardiovascular disease (CVD) continues to be the first cause of mortality in developed countries. Moreover, far from diminishing, the cardiovascular risk factors leading towards the development of CVD are on the rise. Therefore, the preventive and therapeutic management which is currently in place is clearly not enough to stop this pandemic. In this context, a major resurgence in interest in lipoprotein (a) [Lp(a)] has occurred in light of its association with CVD. This series aims to review the basic and clinical aspects of Lp(a) biology. Specifically, the present review considers the current situation regarding the influence of lifestyle, hormones and other physiological or pathological conditions on Lp(a) plasma concentrations which might mitigate the harmful effects of this lipoprotein.
Summary written by lp-a.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.